Try The Drug Club risk-free for 30 days Trial terms

Furosemide 20/40/80 mg tabs — $0 with Membership

Furosemide 20/40/80 mg tabs has an active canonical formulary match. No-additional-cost pricing is subject to its listed supply, quantity, fill, and fulfillment limits.

Furosemide 20/40/80 mg tabs Pricing

Pricing typePrice
TheDrugClub$0 with membership
Typical Retail$153.00

Free with membership subject to the listed formulary limits.

About Furosemide 20/40/80 mg tabs

Furosemide 20/40/80 mg tabs is a prescription medication. Ask your doctor if Furosemide 20/40/80 mg tabs is right for you.

Other strengths and forms of Furosemide

Conditions Treated with Furosemide 20/40/80 mg tabs

How to Check Furosemide 20/40/80 mg tabs Pricing

  1. Join TheDrugClub for $19.95/month
  2. Receive your member card by email
  3. Present your card at a participating pharmacy
  4. Check active-formulary eligibility or available membership pricing

Furosemide 20/40/80 mg tabs at Participating Pharmacies

Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Peripheral Edema/Hypertension (Diuretics)

What Furosemide 20/40/80 mg tabs is approved for (FDA label)

Edema Furosemide tablets are indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide Tablets are particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone.

Source: Read the full FDA label on DailyMed. Label effective date: August 17, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Furosemide 20/40/80 mg tabs (FDA label)

Adverse reactions are categorized below by organ system and listed by decreasing severity.

Source: FDA prescribing information (DailyMed). Set ID: dba00759-87b4-4ecf-998e-ba03ed3d2f1a. SPL document ID: 593ecae2-6f71-f39c-e063-6394a90abb6c. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Furosemide 20/40/80 mg tabs (FDA label)

Furosemide tablets are contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide.

Source: FDA prescribing information (DailyMed). Set ID: dba00759-87b4-4ecf-998e-ba03ed3d2f1a. SPL document ID: 593ecae2-6f71-f39c-e063-6394a90abb6c. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Furosemide 20/40/80 mg tabs (FDA label)

WARNINGS In patients with hepatic cirrhosis and ascites, furosemide therapy is best initiated in the hospital. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma; therefore, strict observation is necessary during the period of diuresis. Supplemental potassium chloride and, if required, an aldosterone antagonist are helpful in preventing hypokalemia and metabolic alkalosis. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued. Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.

Source: FDA prescribing information (DailyMed). Set ID: dba00759-87b4-4ecf-998e-ba03ed3d2f1a. SPL document ID: 593ecae2-6f71-f39c-e063-6394a90abb6c. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Start Your Risk-Free Trial
Start Your Risk-Free Trial